Bayer, Hologic Collaborate on Contrast-Enhanced Mammography

Bayer and Hologic, Inc. announced they will collaborate to deliver a coordinated solution for contrast-enhanced mammography. Contrast-enhanced mammography is a sensitive and relatively low-cost breast imaging modality that can be used to support breast cancer diagnosis and help to guide treatment.

The offering brings together Hologic’s mammography technologies and Bayer’s contrast-enhanced mammography contrast delivery system, the MEDRAD Stellant FLEX Computed Tomography (CT) Injection System. The MEDRAD Stellant FLEX CT Injection System with Certegra Workstation is the first and only CT injection system 510(k) cleared with an additional contrast-enhanced mammography application. By working together, Hologic and Bayer are streamlining the purchasing process for radiologists and imaging facilities, providing a seamless set-up and ongoing, supportive educational resources.

"We are thrilled to work with Hologic to increase access to this emerging breast imaging modality,” said Sven Schmidt, Head of Region Americas Radiology at Bayer. “Together we will deliver an innovative and coordinated solution for both patients and healthcare professionals alike.”

The American Cancer Society estimates that approximately 310,720 new cases of invasive breast cancer will be diagnosed in women in 2024 and approximately 42,250 women will die. Contrast-enhanced mammography is a breast imaging modality and the value of contrast-enhanced mammography as an adjunct to mammography is affirmed by an increasing number of independent scientific publications. Contrast-enhanced mammography can be performed as part of an everyday clinical practice and used in various clinical settings, such as inconclusive findings in previous imaging procedures.